Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 6Carcinoma, Non-Small-Cell Lung 4Squamous Cell Carcinoma of Head and Neck 3Lung Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Neoplasm Metastasis 2Cholangiocarcinoma 2Vulvar Neoplasms 1Vaginal Neoplasms 1Urothelial Bladder Carcinoma 1Urinary Bladder Neoplasms 1Thyroid Carcinoma, Anaplastic 1Thymoma 1Sarcoma 1Recurrence 1Rectal Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oligometastatic Prostate Cancer 1Neoplasms 1Metastatic Urothelial Cancer 1Melanoma 1Locally Advanced Pancreatic Cancer 1Locally Advanced Cervical Cancer 1Liver Neoplasms 1Liposarcoma 1Kidney Neoplasms 1Gestational Trophoblastic Disease 1Gastro-enteropancreatic neuroendocrine tumor 1

Interventions

S 1 (combination) 2Oxaliplatin 2Leucovorin 2Gemcitabine 2Fluorouracil 2130-nm albumin-bound paclitaxel 2zimberelimab 1surufatinib 1Radiosurgery 1Irinotecan 1Immunotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Locally Advanced Pancreatic Cancer × zimberelimab × Clear all
NCT06009029 2023-08-24

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Peking University Third Hospital

Phase 2 Not yet recruiting
96 enrolled
Gastrointestinal

Locally Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡